- Home
- SPRY vs BLFS Comparison
SPRY vs BLFS Comparison
Compare SPRY & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPRY | BLFS |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.2M | 923.5M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SPRY | BLFS |
|---|---|---|
| Price | $7.96 | $20.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $40.00 | $32.00 |
| AVG Volume (30 Days) | ★ 1.6M | 330.7K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.27 |
| EPS | N/A | ★ 0.02 |
| Revenue | $84,278,000.00 | ★ $96,214,000.00 |
| Revenue This Year | $87.40 | $19.73 |
| Revenue Next Year | $81.64 | $17.82 |
| P/E Ratio | ★ N/A | $1,060.00 |
| Revenue Growth | N/A | ★ 16.97 |
| 52 Week Low | $6.66 | $17.86 |
| 52 Week High | $18.63 | $29.57 |
Technical Indicators
Market Signals| Indicator | SPRY | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 48.00 |
| Support Level | $7.53 | $19.71 |
| Resistance Level | $8.61 | $26.14 |
| Average True Range (ATR) | 0.50 | 0.96 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 12.50 | 35.56 |
Price Performance
Historical ComparisonAbout SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.